Gentian Diagnostics ASA OSL:GENT:
ENTERS EXCLUSIVE AGREEMENT WITH GLOBAL DIAGNOSTICS COMPANY
Gentian Diagnostics Enters Exclusive Agreement With Global Diagnostics Company
Gentian Diagnostics ASA on 6ix
Earlier from Gentian Diagnostics
- Gentian Diagnostics Says Prioritizes Refinement, Causing Minor Ruo Delay
- Gentian Diagnostics presents at the DNB Nordic Healthcare Conference
- Financial calendar
- GENT: Strong Q3 growth driven by U.S. sales and Cystatin C, with robust margins and advancing R&D
- Gentian Diagnostics: Invitation to presentation of third quarter results
Later from Gentian Diagnostics
- Gentian Diagnostics invites to NT-proBNP educational webinar
- Gentian Diagnostics: Invitation to presentation of fourth quarter results
- GENT: Record 2025 sales, strong US growth, new partnership, and NT-proBNP development setback
- Mandatory notification of trade
- Gentian Diagnostics: Annual report 2025
Follow Gentian Diagnostics into a list and get an email when it puts out news.
Follow Gentian Diagnostics